-
Study aim
-
Evaluation of therapeutic effects of Nigella sativa extract on serum Brain-Derived Neurotrophic Factor (BDNF) and depression and anxiety score in patients with depression referred to Artesh 505 hospital
-
Design
-
Clinical trial with control group with parallel groups, phase 2-3 on 50 patients
-
Settings and conduct
-
This study will be performed in 505 Artesh Hospital in Tehran and patients with depression will be treated with Nigella sativa capsules. Before and 6 weeks after treatment, the severity of depression as well as the level of serum BDNF in them will be measured and compared with the beginning of the study.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: age between 18 and 65 years, having Major Depression, referring to the 505 Artesh Hospital, treated only with sertraline, moderate to severe depression, having the written informed consent to participate in the study
Exclusion criteria: failure to take medication regularly, drug intolerance, allergy to Nigella sativa, having systemic diseases, pregnancy or breastfeeding in women, tendency to leave during the study
-
Intervention groups
-
Intervention group: Patients in this group will be evaluated for depression severity and serum BDNF after entering the study. Patients will be then treated with capsules containing 1000 mg of Nigella sativa extract daily along with sertraline. After 6 weeks, the patients' depression level as well as the level of serum BDNF in them will be measured again.
Control group: Patients in this group will be evaluated for depression severity and serum BDNF after entering the study. Patients will be then receiving placebo capsules, daily, containing starch along with sertraline. After 6 weeks, the patients' depression level as well as the level of serum BDNF in them will be measured again.
-
Main outcome variables
-
Severity of depression and the level of serum BDNF